...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AGM Content

We could have watched the science develop from the sidelines while keeping our money working elsewhere.  For me RVX and Zenith have been a multi year disappointment. I do hope that these companies blow the doors off big Pharma and actually have something that sees the light of day commercially.  

 

At this point I am prepared to take a total loss rather than sell for the pittance being offered.  

 

GLTA

Share
New Message
Please login to post a reply